Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-3.57% $2.43
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 16.99 mill |
EPS: | -4.61 |
P/E: | -0.530 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 6.99 mill |
Avg Daily Volume: | 0.121 mill |
RATING 2024-04-25 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.530 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.09x |
Company: PE -0.530 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.10 - 2.76 ( +/- 13.46%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-04 | Luthringer Remy | Buy | 100 450 | Employee Stock Option (right to buy) |
2023-10-04 | Race Geoff | Buy | 87 050 | Employee Stock Option (right to buy) |
2023-10-04 | Ahlholm Frederick W | Buy | 42 850 | Employee Stock Option (right to buy) |
2023-09-27 | Hasler Hans Peter | Buy | 12 500 | Stock Option (right to buy) |
2023-09-27 | Van Heek G Jan | Buy | 12 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
34.35 |
Last 97 transactions |
Buy: 4 702 257 | Sell: 460 450 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $2.43 (-3.57% ) |
Volume | 0.0057 mill |
Avg. Vol. | 0.121 mill |
% of Avg. Vol | 4.75 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.